Related Experiment Video
Updated: Jan 16, 2026

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Intensification of diuretic therapy in pulmonary hypertension - a retrospective evaluation of hemodynamic and
Adam Rafałowicz1, Jakub Mierzejewski1, Łukasz Czuba1
1Department of Cardiology, Medical University of Bialystok, Poland.
Purpose:
Diuretics are first-line medication in the management of volume overload in pulmonary hypertension (PH). Their impact on the hemodynamic and functional parameters has not been studied. This study analyzes the impact of intensified diuretic therapy on patients deterioration.
Methods:
The retrospective analysis included 38 patients who were divided into Group 1 (n = 24, no change in the equivalent diuretic dose or treatment without diuretics) and Group 2 (n = 14, increase in the equivalent diuretic dose). Measurements at baseline and after 6 months included echocardiographic parameters, 6-min walk test distance (6MWTd), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP).
Results:
In the initial assessment of the studied parameters, Group 2 had a significantly greater inferior vena cava diameter (IVCd) and right ventricle internal diameter in diastole (RVIDd), trends towards greater right atrium area (RAA), lower tricuspid annular plane systolic excursion (TAPSE), and greater NT-proBNP values compared to Group 1. Over the 6-month follow-up period, Group 1 had a significant increase in IVCd, systolic pulmonary artery pressure (sPAP), significant decrease in TAPSE/sPAP ratio and trends towards increased mean pulmonary artery pressure (mPAP) and 6MWTd values. Group 2, on the other hand, had no significant worsening, which reflects a stabilizing impact of intensified diuretic therapy.
Conclusion:
Intensified diuretic therapy in patients with PH and fluid overload appears to stabilize exercise capacity and prevent deterioration of cardiac function over a 6-month period.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Heart Failure II: Pathophysiology

